Real-World Evidence

32: Initial Findings from the Multi-Institutional Sarcomatoid Renal Cell Carcinoma Consortium (SaRCC)

33: Real- World Treatment Patterns and Outcomes of Patience Receiving First- Line Nivolumab plus Ipilimumab for Relapsed or Metastatic Renal Cell Carcinoma (mRCC)

34: Real-world performance of genomic, histologic, and radiographic features in predicting long-term outcomes in patients with clear cell renal cell carcinoma treated with first-line immunotherapy-based combination regimens.

35: Real-world (RW) outcomes of nivolumab plus ipilimumab (N+I) versus pembrolizumab plus axitinib (P+A) for first-line (1L) treatment of advanced renal cell carcinoma (aRCC)

36: Early experience with adjuvant pembrolizumab in high-risk RCC post nephrectomy

37: Clinical outcomes for mRCC patients ineligible for front-line clinical trials

38: Real-world Treatment Patterns and Clinical Outcomes Among patients with Metastatic Renal Cell Carcinoma (mRCC) Post Immune-oncology (IO) and Tyrosine Kinase Inhibitors (TKIs)

39: Prospective noninterventional study of cabozantinib treatment following VEGF-targeted therapy in patients with advanced renal cell carcinoma: post hoc analysis of patients with concomitant radiotherapy

40: Surveillance is more common than kidney-sparing intervention for cT1 renal masses in patients with chronic kidney disease – analysis from the MUSIC-KIDNEY statewide collaborative

41: Real-world treatment outcomes of first-line axitinib plus pembrolizumab by IMDC risk score for patients with advanced renal cell carcinoma in the United States.

75: Unveiling the Enigmatic: An Encounter of Advanced Renal Cell Carcinoma Disguised as Recurrent Epistaxis